RECURRENT ENDOMETRIAL CARCINOMA

This early-stage study tests a drug called talazoparib together with radiation therapy for people whose gynecologic cancer (like ovarian, endometrial, or cervical) has returned after previous treatment. The main goal is to find the safest dose and see how well the combination wor…

This study tests whether combining two drugs—avelumab (an immunotherapy) and M1774 (a targeted pill)—can shrink or slow the growth of recurrent endometrial cancer in people whose tumors have a specific genetic change (ARID1A mutation). About 25 participants will receive the combi…

This early-stage study tests whether combining two drugs (lenvatinib and pembrolizumab) with a short course of pelvic radiation is safe and effective for people with recurrent or inoperable endometrial cancer that is mismatch repair proficient (pMMR). About 18 participants will r…

This early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer cell growth. …

This study compares three treatment combinations for advanced or recurrent endometrial cancer with specific genetic features (pMMR and TP53 mutated). Participants receive either standard chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), or chemotherapy…

This study tests a combination of two drugs, nab-sirolimus and letrozole, in people with advanced or recurrent endometrioid endometrial cancer. The goal is to see if the combination can shrink or control tumors. About 29 participants will receive the treatment, and researchers wi…

This study is for women whose ovarian or endometrial cancer has returned or not gone away and has a specific change in the RAS gene. It compares taking two drugs (selumetinib and olaparib) versus selumetinib alone. The goal is to see if the combination can shrink tumors or keep t…

This study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants wi…

This study screens patients with advanced solid tumors to find genetic changes in their cancer cells. Based on those results, patients may be matched to a treatment trial that targets their specific tumor mutations. The goal is to improve how doctors choose combination therapies …

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…